ACS Chem Neurosci Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19

[tetano]

ACS Chem Neurosci


. 2020 May 20.
doi: 10.1021/acschemneuro.0c00288. Online ahead of print.
Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19


Ruqaiyyah Siddiqui ¹ , Naveed Ahmed Khan ¹



Affiliations

• PMID: 32432466
• DOI: 10.1021/acschemneuro.0c00288

Abstract

There is mounting evidence of the central nervous system manifestations associated with COVID-19, particularly in severe cases. Up to 25% of COVID-19 cases exhibit neurological manifestations associated with COVID-19. In view of the devastating nature of the disease due to severe acute respiratory syndrome coronavirus 2, here we debate intranasal drug delivery, in addition to intravenous delivery, as a therapeutic strategy in the management of COVID-19 cases with central nervous system involvement.

Keywords: COVID-19; central nervous system; intranasal; neurological manifestation; severe acute respiratory syndrome coronavirus 2.